Multiple Sclerosis Association of America Launches Mobile Phone App for the MS Community
My MS Manager is the Multiple Sclerosis Association of America's new mobile phone application, provided free of charge to individuals with multiple sclerosis (MS) or their care partner to use on their iPhone, iPad or iPod touch. Developed in conjunction with Ringful Health, My MS Manager is available now for download in the Apple iTunes Store.
Multiple Sclerosis Emerging Therapies Collaborative
We are proud to announce the launch of the Multiple Sclerosis Emerging Therapies Collaborative. The Collaborative - which includes the members of the MS Coalition, the American Academy of Neurology, and the VA Multiple Sclerosis Centers of Excellence East and West - has as its mission:To develop and disseminate timely, evidence-based resources to persons affected by multiple sclerosis and health care professionals, in order to promote optimal, individualized treatment of the disease by facilitating effective communication and medical decision-making.
Oral Cladribine Denied FDA Aproval
EMD Serono, Inc., makers of Cladribine Tablets (an oral formulation of cladribine), announced today that they received a complete response letter (CRL) from the United States Food and Drug Administration (FDA). The FDA issues a CRL when it has completed the review of an application, but is not able to approve the application without additional information. The announcement was disappointing to members of the MS Community, who where hoping to see another option added to the list of available disease-modifying therapies for the long-term treatment of MS.
March is MS Awareness Month
The Multiple Sclerosis Association of America (MSAA) encourages everyone to take time this March to learn about multiple sclerosis (MS).
MSAA Survey Reveals Surprising Results: Involuntary Crying and Laughing is Reported by More People With MS than Expected
MS can impact not only physical and cognitive abilities, but also a person's emotional wellbeing. In cooperation with the research organization Infogroup/ORC and supported by an unrestricted educational grant from Avanir Pharmaceuticals, the Multiple Sclerosis Association of America (MSAA) conducted an independent, online survey of almost 20,000 of its members in the fall of 2010. The purpose of this survey was to better understand the extent and impact of a particularly challenging neurological condition known to occur among people living with MS: pseudobulbar affect (PBA).
NEWS ALERT:Voluntary Recall of Potentially Contaminated Alcohol Prep Products Used with Injected Medications
Triad Group, a Wisconsin-based manufacturing company, is voluntarily recalling all lots of their alcohol prep pads, alcohol swabs, and alcohol swabsticks manufactured under their name (Triad Group), or under third party names (Cardinal Health, PSS Select, VersaPro, Boca/ Ultilet, Moore Medical, Walgreens, CVS, and Conzellin).These lots of alcohol prep products have been recalled as a result of potential contamination with Bacillus cereus-bacteria that could lead to life-threatening infections, particularly in those whose immune system is suppressed and for individuals undergoing surgery. As of January 5, 2011, Triad Group has received one report of a non-life-threatening skin infection.
FDA Extends the Review Period for Oral Cladribine
Cladribine is an investigational oral drug being studied for the long-term treatment of relapsing forms of multiple sclerosis (MS). It was submitted to the United States Food and Drug Administration (FDA) for approval earlier this year, receiving Fast Track status in July 2010. Fast Track status reduces the FDA's review time from 10 months down to six – and a decision was expected by November 28, 2010. However, the agency has extended the review time by three months, with a decision now anticipated by February 28, 2011.
FDA Approves Nuedexta to Treat Pseudobulbar Affect (PBA)
* Updated December 3, 2010*
On October 29, 2010, Avanir Pharmaceuticals, Inc. announced the approval of Nuedexta™ by the Food and Drug Administration (FDA) for the treatment of pseudobulbar affect (PBA) associated with certain neurological conditions, including multiple sclerosis (MS). PBA is characterized by uncontrolled, inappropriate, and/or exaggerated episodes of crying, laughing, or other emotional display. PBA occurs involuntarily with little or no stimulation to invoke such a response. It can greatly impact social situations and overall quality of life, both for the patient and his or her family.
FDA Approves First Oral Treatment for Relapsing Forms of MS
Novartis Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Gilenya (fingolimod) as a first-line treatment for relapsing forms of multiple sclerosis (MS). Gilenya is the first oral disease-modifying therapy available for the long-term treatment of MS. The approval of a treatment that may be taken orally (by mouth), versus injection or infusion, is exciting news for members of the MS community..
FDA Committee Recommends the Approval of FTY720
The oral medication FTY720 (fingolimod) has moved another step closer to approval as a new disease-modifying therapy for MS. The United States Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs Advisory Committee reviewed the clinical trial data submitted by Novartis Pharmaceuticals Corporation (makers of FTY720), and reported its findings at a meeting held on June 10, 2010.
Phase 2 CHOICE Study Reports Positive Effects with Daclizumab
Biogen Idec and Facet Biotech Corporation, developers of daclizumab, report that when added to an interferon regimen, this drug reduces the number of new or enlarged MS lesions in patients with active, relapsing forms of MS. Additionally, daclizumab showed an increase in the number of a certain type of cell that helps to regulate the immune system. These results were published in the online edition of The Lancet Neurology and in the April 2010 issue of The Lancet Neurology.
Continued Efficacy and Safety Seen with 15-Year Evaluation of Copaxone
In February 2010, Teva Pharmaceutical Industries Ltd. announced the publication of their data from 15 years of prospective and continuous evaluation of Copaxone®. The 15-year study findings appeared in the February 2010 issue of the journal, Multiple Sclerosis. Given the positive results, this study has been extended to 20 years, and is presently in its 19th year. Copaxone is given via daily subcutaneous injections and is approved for individuals with relapsing-remitting MS (RRMS).
Positive Study Results with Oral FTY720 Leads to Granting of Priority Review Status by FDA
In January 2010, the results from two large Phase III trials with oral FTY720 (fingolimod) were published in The New England Journal of Medicine. According to a press release from Novartis Pharmaceuticals Corporation (makers of FTY720), the TRANSFORMS and FREEDOMS studies showed positive results in reducing relapses, disability progression, and MRI lesions when MS patients were given FTY720.
FDA Approves Botox® for the Treatment of Upper Extremity Spasticity
The United States' Food and Drug Administration (FDA) has approved Botox® (onabotulinumtoxin A) for the treatment of spasticity in the flexor muscles of the elbow, wrist, and fingers in adults. Manufactured by Allergan, Inc., this drug is administered via injection by a medical professional and is available through prescription only.
March is MS Awareness Month
The Multiple Sclerosis Association of America (MSAA) encourages everyone to take time this March to learn about multiple sclerosis (MS) and discover all of the programs and services MSAA offers to everyone affected by MS.
In Memory of Jimmie Heuga (1943-2010)
Jimmie Heuga, founder of The Heuga Center for Multiple Sclerosis in Colorado , passed away on February 8, 2010. Renamed "Can Do Multiple Sclerosis," this center continues to carry on Heuga's philosophy and passion for teaching individuals with MS to live life to the fullest.
Ampyra™ Approved to Improve Walking for Individuals with MS
The United States' Food and Drug Administration (FDA) has approved Ampyra™ (dalfampridine), an oral, timed-release medication developed to improve the conduction of impulses between damaged nerves of the central nervous system (CNS).
Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis
A comprehensive update on chronic cerebrospinal venous insufficiency (CCSVI) and multiple sclerosis (MS) featuring MSAA's Chief Medical Officer Dr. Jack Burks.
Research News Fall 2009
In addition to the recent approval of Extavia, other drug updates include Fampridine-SR, oral cladribine, Copaxone, Tysabri, and fingolimod.
Flu Vaccines for the 2009/2010 Flu Season
Two flu vaccines, the seasonal flu and the H1N1 ("swine flu") vaccines, will be available for the 2009/2010 flu season. The seasonal flu vaccine protects individuals from three types of flu and is currently available. The H1N1 flu vaccine protects individuals from the newest type of flu, which was first detected in people living in the United States in April 2009. The H1N1 vaccine is expected to be available in early to mid-October 2009.
Multiple Sclerosis Association of America Honored for Excellence in Communication
The Multiple Sclerosis Association of America (MSAA) received four communications awards, which included two APEX Awards and two National Health Information Awards for several pieces of work.
Extavia Receives FDA Approval for Treatment of MS
On August 14, 2009, the United States Food and Drug Administration (FDA) approved Extavia® (interferon beta-1b) for the treatment of relapsing forms of multiple sclerosis (MS).
2009 MS Research Update
Based on the positive response to the "MS Research Updates" appearing in the Summer 2007 and 2008 issues of The Motivator, this article incorporates new information about the six approved disease-modifying therapies (DMTs), as well as experimental drugs currently being studied for the treatment of MS
Dirucotide (MBP8298) Update
On July 27, 2009, Eli Lilly and BioMS Medical Corporation announced that dirucotide did not meet the primary endpoint of the MAESTRO-01 study, which was the delay of disease progression in secondary-progressive MS (SPMS) as measured by EDSS (Expanded Disability Status Scale).
MSAA Wins STEVIE Award
The Multiple Sclerosis Association of America 's (MSAA) educational web video series, A Closer Look , recently won the highly acclaimed Stevie Award in the category of Interactive Multimedia/Public Information.
Spring 2009 Research Update
Featuring information on oral cladribine,oral BG-12, and dirucotide
March is Multiple Sclerosis Awareness Month
During the month of March, the Multiple Sclerosis Association of America (MSAA) is asking everyone to become more involved with the MS community. Please join us and find out how you can help.
Results Announced from the Phase II Study of Dirucotide (MBP8298) in RRMS Patients
On January 30, 2009, dirucotide’s developer (BioMS Medical Corp.), announced the results of MINDSET-01, an exploratory phase II clinical trial designed to evaluate the effectiveness and safety of dirucotide in patients with RRMS.
Fall 2008 Research Update
Featuring highlights from the 2008 World Congress on Treatment and Research in Multiple Sclerosis.
Resource DetectiveSM Program Marks One Year Anniversary
During its first year the Resource Detectives program energized a group of 4,000 “detectives” to locate and report over 60,000 resources for the multiple sclerosis (MS) community. Areas of focus include: disability programs, employment, financial assistance, health and wellness, housing information, legal assistance, social security, and many more. The information gathered is used by MSAA’s Helpline staff in assisting individuals affected by MS throughout the country..
New Thinner Needle and New Autoinjector for Betaseron
A thinner needle will soon be available for individuals taking Betaseron® (interferon beta-1b) for the long-term treatment of MS. The thinner needle is being offered as a way to potentially help reduce the pain and anxiety often associated with injections.
Changes to Tysabri's Labeling
Two changes have recently been made to the labeling and prescribing information for Tysabri® (natalizumab). Manufactured and marketed by Biogen Idec and Elan, Tysabri is approved by the United States Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS) as well as Crohn's disease.
Summer Research Update 2008
Numerous trials are currently being conducted to determine the safety and effectiveness of medications for the treatment of multiple sclerosis (MS). Trials include FDA-approved drugs, experimental drugs (such as oral medications, monoclonal antibodies, and other treatments), as well as various combinations of drugs and doses
Two new cases of progressive multifocal leukoencephalopathy (PML), which is an often-fatal viral infection of the brain, have been reported in patients taking Tysabri® (natalizumab) for the long-term treatment of MS. These two cases were reported to the United States Food and Drug Administration (FDA) on July 31, 2008. These are the first cases to be reported since the drug's re-release in June 2006.
The Multiple Sclerosis Association of America Awarded a Grant to Develop a Life Coaching Program
Through a charitable gift from the Bayer USA Foundation, the Multiple Sclerosis Association of America (MSAA) will develop a Life Coaching program for individuals in the multiple sclerosis (MS) community. This program will provide an innovative way for individuals with MS to interact with each other while developing critical problem-solving strategies. To help teach these skills, life coaches will use real life events to help find practical solutions to daily challenges individuals with MS might face. Life coaches will meet with clients through group sessions over the phone or online.
A Closer Look at MRIs
A Closer Look at The Value of MRIs is now available through the Multiple Sclerosis Association of America’s (MSAA) website. This three part video features: a person with multiple sclerosis (MS) offering a first-hand account on the experience of undergoing an MRI; a neurologist explaining how MRIs work as well as the importance of MRIs to monitor disease progression; and an MSAA representative discussing the financial resources available through MSAA for those seeking their first or follow-up MRI.
Spring Research Update
This research update focuses on trials currently being conducted to determine the safety and effectiveness of medications for the treatment of multiple sclerosis (MS). Trials include FDA-approved drugs, experimental drugs (such as oral medications, monoclonal antibodies, and other treatments), as well as various combinations of drugs and doses.
Multiple Sclerosis Association of America Observes March as Multiple Sclerosis Awareness Month
Join the Multiple Sclerosis Association of America (MSAA) in raising awareness for multiple sclerosis (MS) during the month of March. MSAA will be hosting various events designed to expand knowledge, understanding, and support of individuals whose lives are affected by multiple sclerosis. MSAA will also join other MS organizations to call on Congress for increased federal funding for MS research.
MSAA's Public Service Announcement Offers Information on the Importance of Disease Modifying Therapies for MS
On November 25, 2007 MSAA began airing two public service announcements nationwide that encourage individuals with multiple sclerosis (MS) to adhere to an MS treatment plan, including one of the FDA-approved disease modifying therapies. MSAA’s Chief Medical Officer Dr. Jack Burks recommends that individuals with MS consult their physician, and if appropriate, begin treatment as soon as possible. Below are some helpful links on MS medications, MS, and MSAA.
MSAA Enhances Website With New Copy and Technology
Visitors to the Multiple Sclerosis Association of America (MSAA) website, msassociation.org, may have noticed some changes. Over the past few months, a new design was unveiled and various enhancements were made providing the multiple sclerosis (MS) community with the resources and tools they need at their finger tips
MS Coalition Honored at The Heuga Center's 22nd Annual Autumn Benefit
On Tuesday, October 23, 2007 the Multiple Sclerosis Coalition will be honored at The Heuga Center's Annual Autumn Benefit at the St. Regis Hotel in New York City. At the benefit, MSAA's President and CEO Doug Franklin will be accepting The Heuga Center's CAN DO award, on behalf of the Multiple Sclerosis Coalition. Doug Franklin will be accepting this honor as president of the MS Coalition, an affiliation of independent MS organizations dedicated to the enhancement of the quality of life for all those affected by multiple sclerosis.
MSAA Publishes A Booklet About Depression and MS
Understanding and Treating Depression in Multiple Sclerosis is the most recent publication produced by the Multiple Sclerosis Association of America (MSAA).The booklet serves as a resource on depression for both patients and families affected by multiple sclerosis (MS). Author Allison Shadday, LCSW, who has MS, provides an in-depth understanding of depression in MS and focuses on such topics as the hidden symptoms of depression; warning signs; treatment options; and tips for fighting the effects of depression.
Summer 2007 Research Update
Numerous trials are currently being conducted to determine the safety and effectiveness of medications for the treatment of multiple sclerosis (MS). Trials include FDA-approved drugs, experimental drugs (such as oral medications, monoclonal antibodies, and other treatments), as well as various combinations of drugs and doses.
Help MSAA by Shopping At MACY's
From now until October 1, 2007, anyone who gives a gift of $5 or more will be sent an official MACY’S “Shop for a Cause” day card. This card can be used on October 13, 2007, and will give you 20% off any purchases for that day. This is a win-win situation. You will be helping enrich the quality of life for individuals with Multiple Scleroses, and in return, you can treat yourself to a shopping trip at MACY’S store!!
Multiple Sclerosis Association of America Receives A Telly Award
The Silver Telly was awarded to MSAA and VCS, a video production company located in Mount Laurel, New Jersey, for the web video “A Closer Look At Multiple Sclerosis Symptoms, Part 1.” This video is the first in a series titled “A Closer Look,” which is part of MSAA’s Multiple Sclerosis Information (MSi) Program. The MSi Program provides viewers with an extensive resource guide on multiple sclerosis (MS) and helps clients acquire the support they need while coping with the challenges of MS.
Multiple Sclerosis Association of America Wins Two APEX Awards
The Multiple Sclerosis Association of America (MSAA) was honored twice in the 2007 APEX Awards competition. Mommy’s Story, MSAA’s children’s booklet, received the APEX Grand Award for One-of-a-Kind Publication. MSAA also earned a Publication Excellence Award for their quarterly magazine, The Motivator. This was the first time MSAA entered the APEX Award competition.
EMD Serono Offers a New Patient Assistance Program for Rebif®
As a way to expand access to therapy, a new patient assistance program titled MS LifeLines® Access Made Simple was launched on July 2, 2007 by EMD Serono. According to EMD Serono, "The program provides simplified and affordable access to therapy for people with relapsing forms of multiple sclerosis (MS) who have either been newly prescribed Rebif (interferon beta-1a) by their physician or who have restarted Rebif therapy after having discontinued for more than 90 days." All eligible patients will receive a supply of Rebif up to one year, regardless of income, with no more than a $50 co-payment. After one year, patients who are still unable to obtain full insurance coverage for Rebif can apply to the MS LifeLines Patient Assistance Program (PAP), which provides financial support to people who cannot otherwise afford therapy.
Multiple Sclerosis Association of America Debuts MSi Program
A new web video initiative titled MSi (Multiple Sclerosis Information) has been launched by the Multiple Sclerosis Association of America (MSAA). Targeted to individuals with MS, the video series A Closer Look can be accessed on MSAA’s website. The first video, A Closer Look at Multiple Sclerosis Symptoms – Part 1, is divided into four segments: Effective MS Symptom Management featuring Jack Burks, MD; Understanding Depression and MS featuring Allison Shadday, LCSW; Learning about Involuntary Emotional Expression Disorder featuring Daniel Wynn, MD; and Managing Spasticity featuring Donald Barone, DO.
Primary-Progressive Multiple Sclerosis Update
Historically, primary-progressive multiple sclerosis (PPMS) has seemingly taken a back seat to other types of multiple sclerosis (MS). By far, the largest amount of information published about research and treatments for multiple sclerosis (MS) has been in reference to relapsing-remitting and secondary-progressive forms of MS (RRMS and SPMS respectively).
Multiple Sclerosis Association of America Night at the Philadelphia Phantoms
Please join MSAA and the Philadelphia Phantoms in support of MSAA programs and services on Sunday, April 3, 2005 at 6pm at the Wachovia Spectrum as the Phantoms take on the Wilkes-Barre/Scranton Penguins.
Voluntary Suspension of Tysabri ® for Treatment of Multiple Sclerosis
On February 28, 2005, Biogen Idec and Elan Pharmaceuticals announced a voluntary suspension in the marketing of Tysabri®. Commercialization is suspended and physicians are asked to suspend dosing of Tysabri immediately.
Multiple Sclerosis Association of America Adds Western Regional Office in San Francisco, California
The Multiple Sclerosis Association of America (MSAA) has expanded its regional offices from five to six with the addition of the Western Regional Office. The Western Region is headquartered in San Francisco, California and under the direction of Amanda Montague (pronounced “Mon-taig´”) . The region encompasses California, Arizona, Hawaii, Nevada, Oregon, and Utah. Along with the addition of the Western Region, MSAA also re-aligned its other five regional offices to provide each state with a regional office.
FDA Approves Tysabr® (formerly Antegren) for Treatment of Multiple Sclerosis
The United States Food and Drug Administration (FDA) has approved Tysabri® (natalizumab), formerly known as Antegren®, for the treatment of relapsing-remitting forms of multiple sclerosis (RRMS).
FDA Decision on Antegren Expected Soon
On or before November 25, 2004, the U.S. Food and Drug Administration (FDA) is expected to announce its decision about whether or not Antegren® (natalizumab) will be approved as a treatment for multiple sclerosis. Six months ago, the makers of Antegren (Biogen Idec and Elan Corporation), submitted an application to the FDA for early approval of this drug for MS. The application was submitted one year sooner than planned. The decision came after the manufacturers reviewed the one-year data from the two ongoing, two-year phase III trials.
Medicare Modernization Act
As part of the Medicare Modernization Act, Medicare will extend coverage to prescription medications used to treat multiple sclerosis as well as other serious conditions including cancer, rheumatoid arthritis, and pulmonary hypertension. This Act is part of a demonstration project that will help up to 50,000 beneficiaries. To be eligible for the program, a beneficiary must be enrolled in Medicare Part A and Part B, and Medicare must be the primary payer.
Antegren Submitted One Year Early for FDA Approval
The makers of Antegren® (Biogen Idec and Elan Corporation) announced they are going to be submitting an application for approval of Antegren (natalizumab) as a treatment for multiple sclerosis to the U.S. Food and Drug Administration (FDA) one year earlier than planned. They expect to submit the filing mid-year 2004. The decision came after reviewing the one-year data from the two ongoing two-year phase III trials. The companies did not disclose the one-year data to protect the integrity of the trial.
MSAA Names Joseph R. King Chair of the Board of Directors
Joseph R. King, Director of External Affairs for Verizon Communications, Inc. was recently appointed chair of the Multiple Sclerosis Association of America's (MSAA) Board of Directors effective June 4, 2004.
Oral Cladribine Efficacy Trials Slated to Begin This Year
Recently, Serono (makers of Rebif) and Ivax Corporation announced their test results from two clinical trials with a new oral formulation of cladribine. The study results showed that the formulation of oral cladribine has met the targets for an orally administered product, with blood levels of cladribine reaching the desired levels. Cladribine inhibits immune reactions by disrupting the production of certain white blood cells, particularly lymphocytes, which are involved in the disease process of multiple sclerosis. Investigators are planning further efficacy studies of oral cladribine in MS patients for late 2004.
More Patents and Trials Continue with MBP8298
BioMS Medical, based in Edmonton, Alberta, has recently received 17 additional patents for MBP8298 in conjunction with the University of Alberta. In total, 50 patents have been granted to the University of Alberta for MBP8298 in 29 countries worldwide, including three patents issued in the United States. MBP8298 stands for Myelin Basic Protein Peptide and is comprised of 17 amino acids. The drug, which has been in research for 26 years, is going to phase III of clinical trials, with successful results in the pre-clinical, phase I and phase II human clinical trials in Canada.
Multiple Sclerosis Association of America Prsents "The Questions You Have, The Answers You Need"
On Saturday, March 5, 2005, from 10 am-3:30 pm, MSAA is presenting a day long program at the Renaissance Austin Hotel. The program will be in a small group format and will feature Director of the MS Clinic of Central Texas, Edward Fox, M.D., PhD; an expert physical therapist; MS nurse practitioner; and a resource specialist to address YOUR questions and concerns about MS.
Flu Vaccines, MS, and General Flu and Cold Information
Individuals with MS need to pay extra attention to staying healthy and avoiding illness during the flu and cold season. MSAA's Vice President and Chief Medical Officer Jack Burks, MD, advises everyone with MS to consult his or her physician about getting a flu shot. With the shortage of vaccines, individuals with MS qualify as a group which should get priority for receiving a flu shot. Other steps may be taken to reduce one's risk of getting the flu, and this is important for both individuals with MS and others in the household. For those who catch the flu virus or who get a cold, this writing explains how the viruses are transmitted, what the symptoms are, and what treatments are available. Additional warnings about supplements, antibiotics, saunas, and smoking are included
Upcoming MSAA Health Fairs
MSAA is crossing the United States bringing specialized MS Health Fairs to targeted areas. The Health Fairs are funded by a grant from Serno, Inc./ Pfizer,Inc.
Pharmaceutical Companies Latest Drug Reports
The 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) was held in Milan, Italy in September. This prompted pharmaceutical companies to send out press releases with the latest information on their drugs and studies with MS.
MS Blood Test Studied
MS has always been associated with a variety of symptoms that may occur unpredictably and mimic other conditions. In most cases, patients present to the neurologist after their first flare-up of neurological symptoms, which is labeled as a clinically isolated syndrome.
CAMPATH® Shows Promise in the Treatment of MS
Results of several pilot studies with the drug Campath (alemtuzumab) were presented at the annual American Academy of Neurology (AAN) meeting in Honolulu on April 1, 2003.
Pregnancy Hormone Estriol May Help MS
For many years, the medical community has observed that a womans MS may be less severe during pregnancy. A pregnancy hormone named estriol is produced by the placenta and may cause this remission in symptoms.
Positive Results from Antegren® Trial Published
Last years Winter 2002 issue of The Motivator included the encouraging results of a six-month study investigating the effects of the monoclonal antibody natalizumab Antegren) in 213 individuals with relapsing-remitting and secondary-progressive MS.
Recent studies continue to affirm the safety of vaccinations for people with MS. An evaluation of several reports and trial outcomes by the US Penitentiary Health Services Unit in Terre Haute, IN, concluded that the hepatitis B (HB), influenza, and tetanus vaccines do not increase the risk of developing MS or exacerbating its symptoms.
Limited Baclofen Availability
A shortage of the drug baclofen (Lioresal®), in its oral tablet form, has been reported by Magee Rehabilitation of the Jefferson Health System. Many individuals with MS or other neurologic conditions depend on baclofen to treat spasticity.
Provigil® Among Recommendations in Treatment of MS Fatigue
A Working Group of neurologists has recommended the wake-promoting agent Provigil® (generic name: modafinil), as the first line of treatment for moderate to severe MS fatigue. Provigil was initially approved in the US in 1998 for the treatment of excessive daytime sleepiness and narcolepsy.
Drug Injections for MS Become More Convenient
Betaseron® is now available in the US in a new room-temperature formula. Given via subcutaneous injection every other day for the long-term treatment of relapsing-remitting MS (RRMS), Betaseron previously needed to be refrigerated making travel difficult for people using this medication.